TWI762706B - Glp-1組成物及其用途 - Google Patents

Glp-1組成物及其用途 Download PDF

Info

Publication number
TWI762706B
TWI762706B TW107129632A TW107129632A TWI762706B TW I762706 B TWI762706 B TW I762706B TW 107129632 A TW107129632 A TW 107129632A TW 107129632 A TW107129632 A TW 107129632A TW I762706 B TWI762706 B TW I762706B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
semaglutide
composition
phenol
Prior art date
Application number
TW107129632A
Other languages
English (en)
Other versions
TW201912147A (zh
Inventor
穆勒 愛娃 侯恩
索瑞瑟恩 麥克 杜蘭德
喬金曼 盧德克維斯克
Original Assignee
丹麥商諾佛 儂迪克股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59713860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI762706(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 丹麥商諾佛 儂迪克股份有限公司 filed Critical 丹麥商諾佛 儂迪克股份有限公司
Publication of TW201912147A publication Critical patent/TW201912147A/zh
Application granted granted Critical
Publication of TWI762706B publication Critical patent/TWI762706B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本發明係關於包含不超過0.01%(w/w)苯酚之GLP-1肽索馬魯肽的醫藥組成物、其製備物、包含此類組成物之套組、以及其用途。

Description

GLP-1組成物及其用途
本發明係關於包含GLP-1肽索馬魯肽(semaglutide)之醫藥組成物的領域。
已知GLP-1肽在液體溶液中易於出現穩定性缺乏，例如物理穩定性缺乏。因此，需要穩定性甚至更佳的包含GLP-1肽之液體醫藥組成物。此類改進之穩定性可為物理穩定性及/或化學穩定性。
在一些具體實例中，本發明係關於包含索馬魯肽及不超過0.01%(w/w)苯酚之液體醫藥組成物。在一些具體實例中，本發明係關於包含如本文中所定義之醫藥組成物的套組。在一些具體實例中，本發明係關於如本文中所定義之用於醫藥的醫藥組成物。
在一些具體實例中，本發明係關於包含GLP-1肽索馬魯肽及不超 過0.01%(w/w)苯酚之液體醫藥組成物。意外地，本發明者發現此類組成物具有改進之化學及/或物理穩定性。在一些具體實例中，組成物不包含苯酚。在一些具體實例中，組成物包含0.01至10mg/ml索馬魯肽。在一些具體實例中，組成物之pH值介於6.0至10.0範圍內，例如pH 7.0至7.8。
在一些具體實例中，本發明之組成物為包含索馬魯肽及不超過0.01%(w/w)苯酚之液體醫藥組成物，其中該組成物a.用於非經腸投予；b.為包含至少60% w/w水之水溶液；或c.進一步包含選自由緩衝劑或等張劑組成之群的一或多種醫藥學上可接受之賦形劑。
在一些具體實例中，本發明之組成物為液體醫藥組成物，其包含索馬魯肽、不超過0.01%(w/w)苯酚及視情況之一或多種醫藥學上可接受之賦形劑，其中調配物用於非經腸投予，例如皮下投予。
在一些具體實例中，本發明之組成物為液體醫藥組成物，其包含索馬魯肽、不超過0.01%(w/w)苯酚、至少60% w/w水以及視情況之一或多種醫藥學上可接受之賦形劑。
在一些具體實例中，如本文中所使用之術語「穩定性」係指索馬魯肽在液體醫藥組成物中之穩定性。在一些具體實例中，穩定性為GLP-1肽之化學穩定性(例如，藉由HPLC所確定，例如本文中之分析(I))，及視情況之GLP-1肽之物理穩定性(例如，藉由硫代黃素T(Thioflavine T)分析所確定，例如本文中之分析(II))。
在一些具體實例中，如本文中所使用之與索馬魯肽有關的術語「化學穩定性」係指索馬魯肽化合物之共價鍵實質上完整。在一些具體實例中，GLP-1肽之化學穩定性藉由HPLC確定，例如本文中之分析(I)。在一些具體實例中，若在在25℃下儲存3個月後，在至少80%(w/v)之該GLP-1肽中其共價鍵為完整的，則組成物具有化學穩定性。在一些具體實例中，索馬魯肽之化學穩定性藉由本文中之分析(IV)確定。
在一些具體實例中，如本文中所使用之與索馬魯肽有關的術語「物理穩定性」係指實質上不形成聚集體之索馬魯肽，例如呈原纖維形式。在一些具體實例中，物理穩定性藉由硫代黃素T分析確定，例如本文中之分析(II)。
在一些具體實例中，本發明之組成物為穩定醫藥組成物。當在本文中使用時，術語「穩定醫藥組成物」係指包含GLP-1肽之醫藥組成物，例如溶液或懸浮液，且其組成物在儲存後包含至少80%(w/v)之該GLP-1肽(例如，在25℃下靜態儲存3個月後)。穩定性測試之儲存條件可為2至8℃，例如5℃，或至少在5℃下2.5年。或者，穩定性測試之儲存條件可為至少4週，例如6週或3個月，視情況在30℃下。此穩定醫藥組成物之儲存條件可為在5℃下1或2年。此穩定醫藥組成物之儲存條件可為在5℃下3年。或者，此儲存之條件可為在25℃下24小時或1週。在又一替代例中，此儲存之條件可為室溫下兩個月，例如多達兩個月。
在一些具體實例中，GLP-1肽之化學穩定性需要至少80%(w/v)(例如至少90%(w/v)或至少95%(w/v))之該GLP-1肽在儲存時段結束時保持其共價鍵完整。在一些具體實例中，GLP-1肽之化學穩定性需要至少95%(w/v)(例如至少97%(w/v)或至少99%(w/v))之該GLP-1肽在儲存時段結束時保持其共價鍵完整。
本發明之組成物包含不超過0.01%(w/w)苯酚。在一些具體實例中，組成物實質上不包含苯酚。
醫藥組成物
術語「醫藥組成物」及「組成物」在本文中可互換使用，且係指 適用於向有需要之個體投予的醫藥組成物。
在一些具體實例中，組成物包含0.01至100mg/ml索馬魯肽。在一些具體實例中，組成物包含0.1至50mg/ml索馬魯肽，例如0.5至25mg/ml或1至15mg/ml。在一些具體實例中，組成物包含0.1至10mg/ml索馬魯肽，例如0.5至5mg/ml或1至2mg/ml。在一些具體實例中，組成物包含0.01至10mg/ml索馬魯肽，例如0.01至5mg/ml。在一些具體實例中，組成物包含不超過9mg/ml索馬魯肽，例如不超過8mg/ml或不超過7mg/ml。在一些具體實例中，組成物包含不超過6mg/ml索馬魯肽，例如不超過5mg/ml或不超過4mg/ml。在一些具體實例中，組成物包含不超過3mg/ml索馬魯肽，例如不超過2mg/ml或不超過1mg/ml。在一些具體實例中，組成物包含至少0.01mg/ml索馬魯肽，例如至少0.02mg/ml或至少0.05mg/ml。在一些具體實例中，組成物包含1.34mg/ml索馬魯肽。
在一些具體實例中，本發明之組成物之pH值介於3至10範圍內，例如pH 6至10或6至9。在一些具體實例中，本發明之組成物之pH值介於pH 6.5至8.5範圍內，例如pH 7.0至7.8。
在一些具體實例中，本發明之組成物包含一或多種醫藥學上可接受之賦形劑。
在一些具體實例中，本發明之組成物包含等張劑，例如丙二醇。在一些具體實例中，等張劑為丙二醇或氯化鈉。
在一些具體實例中，本發明之組成物包含緩衝劑，例如磷酸鹽緩衝劑、TRIS、檸檬酸鹽或緩衝劑緩衝劑。在一些具體實例中，磷酸鹽緩衝劑為磷酸鈉緩衝劑，例如磷酸氫二鈉。
在一些具體實例中，本發明之組成物不包含防腐劑。
本發明之組成物呈液體醫藥組成物形式。在一些具體實例中，液體醫藥組成物為溶液或懸浮液。在一些具體實例中，本發明之組成物呈溶液形 式，例如水溶液。在一些具體實例中，如本文中所使用之術語「水溶液」係指包含至少60% w/w水的溶液。在一些具體實例中，水溶液包含60-99% w/w水。在一些具體實例中，水溶液包含至少75% w/w水，例如至少80% w/w水或至少85% w/w水。在一些具體實例中，水溶液包含至少90% w/w水，例如至少92% w/w水或至少94% w/w水。
索馬魯肽
GLP-1肽索馬魯肽可如WO2006/097537，實施例4中所描述來製備。索馬魯肽亦稱為N6.26-{18-[N-(17-羧基十七醯基)-L-γ-麩胺醯基]-10-側氧基-3,6,12,15-四氧雜-9,18-二氮雜十八醯基}-[8-(2-胺基-2-丙酸),34-L-精胺酸]人類升糖素類肽1(7-37)，見WHO藥物信息第24卷第1,2010期。在一些具體實例中，索馬魯肽可以其完全或部分電離化形式存在於組成物中；例如一或多種羧酸基(-COOH)可去質子化為羧酸酯基團(-COO-)，及/或一或多種胺基(-NH2)可質子化為-NH3+基團。在一些具體實例中，將索馬魯肽添加至呈鹽形式之組成物。
投予及套組
本發明之組成物用於非經腸投予。在一些具體實例中，組成物用於皮下投予。
在一些具體實例中，本發明之組成物每週投予一次。在一些具體實例中，本發明之組成物每日投予一次、每兩天投予一次或每三天投予一次。
在一些具體實例中，本發明係關於一種包含如本文中所定義之醫藥組成物及使用說明書的套組。在一些具體實例中，使用說明書包含藥物包裝插頁。
在一些具體實例中，本發明係關於一種包含如本文中所定義之醫 藥組成物及注射裝置的套組。在一些具體實例中，注射裝置選自由耐用筆及預填充筆組成之群。耐用筆之實例為NovoPen® 4或NovoPen® 5(兩者均來自丹麥的諾佛．儂迪克股份有限公司)。預填充筆之實例為FlexPen®(諾佛．儂迪克股份有限公司，丹麥)。
適應症
在一些具體實例中，本發明之組成物用於醫藥。在一些具體實例中，本發明之組成物可用於以下醫藥治療：(i)預防及/或治療所有形式之糖尿病，諸如高血糖症、2型糖尿病、葡萄糖耐受性異常、1型糖尿病、非胰島素依賴性糖尿病、年輕起病成人型糖尿病(maturity onset diabetes of the young；MODY)、妊娠期糖尿病及/或HbA1C減少；(ii)延緩或預防糖尿病進程，例如2型糖尿病之進程，延緩葡萄糖耐受性異常(impaired glucose tolerance；IGT)發展至需要胰島素之2型糖尿病，及/或延緩非胰島素需要2型糖尿病發展至需要胰島素之2型糖尿病；(iii)例如藉由減少食物攝入、減輕體重、抑制食慾、誘發飽腹感來預防及/或治療飲食障礙，例如肥胖症；治療或預防暴食症、神經性貪食症及/或由投予抗精神病藥或類固醇引發之肥胖症；減少胃運動；及/或延緩胃排空。
在一些具體實例中，適應症為(i)。在一些具體實例中，適應症為(ii)。在又一特定態樣中，適應症為(iii)。在一些具體實例中，適應症為2型糖尿病及/或肥胖症。
在一些具體實例中，方法或用途包含預防、治療、減輕及/或誘發本文中所定義之一或多種疾病或病況。在一些具體實例中，適應症為(i)及(iii)。在一些具體實例中，適應症為(ii)及(iii)。在一些具體實例中，本發明包含投予有效量之GLP-1肽。在一些具體實例中，本發明係關於投予有效量之GLP-1 肽。
一般而言，患有肥胖症之所有個體亦視為患有超重。在一些具體實例中，本發明係關於一種治療或預防肥胖症之方法。在一些具體實例中，本發明係關於一種用於治療或預防肥胖症之組成物的用途。在一些具體實例中，患有肥胖症之個體為人類，諸如成人或孩童(包括嬰兒、兒童及青少年)。身體質量指數(Body mass index；BMI)為基於高度及體重之體脂肪之量度。計算式為BMI=以公斤為單位之重量/以米為單位之高度2。患有肥胖症之人類個體之BMI可為>30；此個體亦可稱為肥胖性的。在一些具體實例中，患有肥胖症之人類個體之BMI可為>35或介於>30至<40範圍內。在一些具體實例中，肥胖症為重度肥胖症或病態肥胖症，其中人類個體之BMI可為>40。
在一些具體實例中，本發明係關於一種(視情況在至少一種重量相關之共生病症存在下)治療或預防超重之方法。在一些具體實例中，本發明係關於一種用於(視情況在至少一種重量相關之共生病症存在下)治療或預防超重之組成物的用途。在一些具體實例中，患有超重之個體為人類，諸如成人或孩童(包括嬰兒、兒童及青少年)。在一些具體實例中，患有超重之人類個體之BMI可為>25，例如>27。在一些具體實例中，患有超重之人類個體之BMI介於25至<30範圍內或介於27至<30範圍內。在一些具體實例中，重量相關之共生病症選自由以下組成之群：高血壓、糖尿病(諸如2型糖尿病)、血脂異常、高膽固醇及阻塞性睡眠呼吸暫停。
在一些具體實例中，本發明係關於一種減輕體重之方法。在一些具體實例中，本發明係關於一種用於減少體重之組成物的用途。根據本發明之經受體重減少之人類的BMI可為>25，例如>27或>30。在一些具體實例中，根據本發明之經受體重減少之人類的BMI可為>35或>40。術語「體重減少」可包括治療或預防肥胖症及/或超重。
在一些具體實例中，如本文中所使用，相對於數目或時間間隔給定之具體值可理解為具體值或理解為約具體值(例如，加或減具體值之百分之10)。
本發明之具體實例
以下為本發明之非限制性具體實例：
1.一種包含索馬魯肽及不超過0.01%(w/w)苯酚之液體醫藥組成物。
2.一種包含索馬魯肽及實質上無苯酚之液體醫藥組成物。
3.如技術方案1或2之組成物，其中該組成物不包含苯酚。
4.如前述技術方案中任一項之組成物，其中該組成物為包含至少60% w/w水之水溶液，例如至少70% w/w水或至少80% w/w水。
5.如前述技術方案中任一項之組成物，其中索馬魯肽之濃度為0.5至10mg/ml之該組成物。
6.如前述技術方案中任一項之組成物，其中該索馬魯肽呈醫藥學上可接受之鹽的形式。
7.如前述技術方案中任一項之組成物，其中該組成物包含一或多種醫藥學上可接受之賦形劑。
8.如前述技術方案中任一項之組成物，其中該組成物包含用於調整pH值的一或多種試劑，例如HCl、NaOH或乙酸。
9.如前述技術方案中任一項之組成物，其中該組成物包含緩衝劑及/或等張劑。
10.如前述技術方案中任一項之組成物，其中該緩衝劑存在於濃度為0.01至50mM之該組成物中。
11.如前述技術方案中任一項之組成物，其中該緩衝劑為磷酸鹽緩衝劑。
12.如前述技術方案中任一項之組成物，其中該磷酸鹽緩衝劑選自由以下組成之群：磷酸二氫鈉、磷酸氫二鈉及磷酸鈉。
13.如前述技術方案中任一項之組成物，其中該等張劑以8mg/ml至50mg/ml(例如14mg/ml至30mg/ml)之該組成物的濃度存在。
14.如前述技術方案中任一項之組成物，其中該等張劑為丙二醇。
15.如前述技術方案中任一項之組成物，其中該組成物不包含防腐劑。
16.如前述技術方案中任一項之組成物，其中該組成物之pH值介於6.0至10.0範圍內。
17.如前述技術方案中任一項之組成物，其中該組成物用於非經腸投予。
18.如前述技術方案中任一項之組成物，其中該組成物用於皮下投予。
19.一種套組，其包含如前述技術方案中任一項之醫藥組成物及使用說明書。
20.一種包含如前述技術方案中任一項之醫藥組成物及注射裝置之套組，該注射裝置用於向個體投予該組成物，其中該注射裝置選自由耐用筆及預填充筆組成之群。
21.如前述技術方案中任一項之醫藥組成物，其用於醫藥。
22.如前述技術方案中任一項之醫藥組成物，其用於治療糖尿病或肥胖症。
23.一種用於預防或治療糖尿病或肥胖症的方法，其中向有需要之個體投予如前述技術方案中任一項之醫藥組成物。
實施例
一般方法及特徵界定
製備索馬魯肽組成物：
除非另外指出，否則索馬魯肽組成物藉由將緩衝劑(例如，磷酸氫二鈉二水合物)、等張劑(例如，丙二醇)及視情況之防腐劑(苯酚)溶解於水中來 製備。將索馬魯肽溶解於其中，使用氫氧化鈉及/或鹽酸將pH值調整至7.4，且最後藉由由0.22μm無菌過濾器過濾對組成物進行滅菌。
製備利拉魯肽(liraglutide)組成物：
除非另外指出，否則利拉魯肽組成物由溶液1及溶液2製備：溶液1藉由將緩衝劑(磷酸氫二鈉二水合物)、等張劑(甘露醇)及視情況之防腐劑(苯酚)溶解於水中來製備。溶液2藉由在緩慢攪拌時溶解利拉魯肽來製備。將溶液1及溶液2混合，使用氫氧化鈉及/或鹽酸將pH值調整至8.15，且最後藉由由0.22μm無菌過濾器過濾來對組成物進行滅菌。
分析(I)：確定索馬魯肽組成物之高分子量蛋白質(High Molecular Weight Proteins；HMWP)含量
使用尺寸排外層析法(size exclusion chromatography；SE-HPLC)來進行對HMWP含量之確定，該尺寸排外層析法使用沃特斯(Waters)胰島素HMWP柱，利用移動相之氯化鈉、磷酸鈉、磷酸及異丙醇等度溶離，且在280nm下檢測。HMWP之含量以%形式給出為相對於HMWP及索馬魯肽單體峰之總面積的早於索馬魯肽單體峰溶離之層析峰(亦即HMWP峰)的組合面積。
分析(II)：經由ThT評估索馬魯肽組成物之物理穩定性
此分析之目的為評估GLP-1肽在水溶液中之物理穩定性。
肽或蛋白質之低物理穩定性可引起澱粉狀蛋白原纖維形式。原纖維為藉由可溶性蛋白質之聚集形成且由β片層結構主導之結構上非常有序的絲狀巨分子結構。成熟原纖維為不溶性且抗降解。出於藥品質量及患者安全起見，期望最小化及控制在治療性肽及蛋白質之醫藥組成物中的原纖維化事件。可藉 由目視檢查樣本來評估蛋白質聚集，包括原纖維化。可藉由使用硫代黃素T(ThT)(對原纖維具有高特異性之小分子指示劑探針)來評估纖維化。當與原纖維結合時，相比於呈溶液狀態之ThT，ThT具有不同螢光標記[Naiki等人(1989)Anal.Biochem.177,244-249；LeVine(1999)Methods.Enzymol.309,274-284]。
提出部分摺疊之肽中間物之形成作為原纖維化之一般引發機制。少量此等中間物成核以形成其上可組合有其他中間物且進行原纖維化之模板。滯後時間對應於時間間隔，其中產生細胞核之臨界量且表觀速率常數(apparent rate constant)為形成原纖維自身之速率。因此，描述於盤讀取器上進行之ThT分析中的滯後時間視為呈溶液狀態之肽組成物之原纖維化傾向之指示。
在進行分析前，將ThT添加至來自H2O中之儲備溶液之樣本直至樣本呈20μM之最終濃度。將包含GLP-1肽之組成物的200μl等分樣本放入各孔中放入有玻璃細珠(2.8至3.2mm，Whitehouse Scientific)之96孔微量滴定盤(光學0.4mL黑色Thermo Scientific Nunc)中。通常，將各樣本之八個複本放在該盤上。該盤用密封帶(Thermo Scientific Nunc)密封。
對ThT螢光發光之在給定溫度下之培養、震盪及量測在BMGFLUOStar Omega或BMG FLUOStar Optima中進行。在40℃下利用2mm振幅以300rpm之的雙軌道搖動來培養該盤。使用穿過450nm濾光器之激發及穿過480nm濾光器之發射量測來進行螢光量測。每20分鐘對盤進行量測，持續所需時間段。各量測之間，如所描述震盪且加熱該盤。
確定臨限值為在1h 13min時間加100 RFU下於該盤上量測之最高ThT螢光(在相對螢光單元(relative fluorescence units；RFU)中)。臨限值隨後用於使用BMG FLUOstar軟體中之「臨限時間(time to threshold)」方法來計算滯後時間。
分析(III)：確定利拉魯肽純度
使用高效液相層析法(high performance liquid chromatography；HPLC)來進行純度確定，該高效液相層析法使用沃特斯XTerraTM MS C18柱，利用兩個移動相之梯度溶離，其中一個移動相為水性磷酸銨緩衝劑(pH8)/乙腈混合物且另一移動相為乙腈/水。檢測在215nm下進行。
分析(IV)：確定索馬魯肽中之雜質總和
使用反相高效液相層析法(reversed phase high performance liquid chromatography；RP-HPLC)來進行索馬魯肽純度之確定，該反相高效液相層析法使用Kinetex C18柱，利用後接兩個移動相之梯度溶離之等度溶離，其中一個移動相為水性磷酸鹽緩衝劑/乙腈混合物且另一移動相為水性乙腈/異丙醇混合物。檢測在210nm下進行。索馬魯肽之純度作為雜質總和以%形式給出為相對於索馬魯肽單體峰之所有層析峰之組合面積。
實施例1：索馬魯肽
在此實驗中測試包含索馬魯肽之組成物。所測試組成物在pH 7.4下於水溶液中含有索馬魯肽(如表1中所說明)、丙二醇(14mg/ml)、磷酸氫二鈉二水合物(1.42mg/ml)及視情況之苯酚(5.5mg/ml)(如表1中所說明)。如本文中在製備之一般方法部分中所描述來製備此等組成物。藉由本文中在實驗開始時所描述之分析(I)且在25℃、30℃或37℃下儲存後來確定由HMWP表示之化學穩定性。藉由本文中所描述之分析(II)來確定由硫代黃素T(ThT)分析表示之物理穩定性。
結果給出於表2及3中。意外地，此等結果顯示相對於含有苯酚之組成物，在不含苯酚之組成物中，索馬魯肽之物理及化學穩定性得到改進。表3 中顯示之結果為8個測試樣本之平均值。
Figure 107129632-A0202-12-0013-1
Figure 107129632-A0202-12-0013-2
Figure 107129632-A0202-12-0013-3
實施例2(參考)：利拉魯肽
鑒於GLP-1化合物利拉魯肽(與索馬魯肽相反)在不含苯酚之組成物中較不化學穩定，實例1之結果亦出人意料。此等結果顯示於表5中。
如下獲得表5中之結果：測試包含利拉魯肽之組成物。所測試組成物在pH 7.4下於水溶液中含有利拉魯肽(如表4中所說明)、甘露醇(36.9mg/ml)、磷酸氫二鈉(1.42mg/ml)及視情況之苯酚(如表4中所說明)。如本文中在製備之一般方法部分中所描述來製備此等組成物。藉由本文中在實驗開始時所描述之分析(III)且在25℃下或在37℃下儲存後來確定由純度表示之化學穩定性。
Figure 107129632-A0202-12-0014-4
Figure 107129632-A0202-12-0014-5
實施例3：索馬魯肽-額外實驗
在此實驗中測試包含索馬魯肽之組成物。所測試組成物在pH 7.0、7.4或7.8下於水溶液中含有索馬魯肽、等張劑(丙二醇(14mg/ml)或氯化鈉(6.3mg/ml))、視情況之緩衝劑(磷酸氫二鈉二水合物(1.42mg/ml)或檸檬酸三鈉二水合物(2.35mg/ml))及視情況之苯酚(5.5mg/ml或0.1mg/ml)；所測試各組成物之細節 顯示於表6中。如本文中在製備之一般方法部分中所描述來製備該等組成物。由HMWP表示之化學穩定性藉由分析(I)確定，且由雜質總和表示之化學穩定性藉由本文中在實驗開始時所描述之分析(IV)且在30℃下儲存後來確定。由硫代黃素T(ThT)分析表示之物理穩定性藉由本文中所描述之分析(II)確定。
結果給出於表7及8中。與實例1之結果一致，此等結果顯示相對於含有5.5mg/ml下之苯酚的組成物，在不具有或具有低苯酚濃度之組成物中，索馬魯肽之物理穩定性及化學穩定性得到改進。結果顯示相對於含有苯酚之組成物，在不含苯酚之包含緩衝劑檸檬酸三鈉二水合物或無緩衝劑或等張劑氯化鈉之組成物中，索馬魯肽之物理穩定性及化學穩定性亦得到改進。相對於含有5.5mg/ml苯酚之組成物，對於類似於不含苯酚之組成物的含有0.1mg/ml苯酚之組成物，化學及物理穩定性得到改進。此針對pH 7.0至7.8且索馬魯肽濃度0.110mg/ml之組成物而展示。
Figure 107129632-A0202-12-0016-6
Figure 107129632-A0202-12-0017-9
DS：索馬魯肽。1物理上不穩定>30℃下1個月。
Figure 107129632-A0202-12-0018-8
結果為8個測試樣本之平均值。DS：索馬魯肽。
儘管已在本文中說明及描述本發明之某些特徵，但一般熟習此項技術者現將想到多種修改、替代、變化及等效物。因此，應瞭解，所附申請專利範圍意欲涵蓋如屬於本發明之真實精神內的所有此類修改及變化。

Claims (15)

  1. 一種液體醫藥組成物，其包含0.1-10mg/mL索馬魯肽(semaglutide)及不超過0.01%(w/w)苯酚，其中該組成物a.用於非經腸投予；b.為包含至少60% w/w水之水溶液；且c.進一步包含選自由緩衝劑或等張劑組成之群的一或多種醫藥學上可接受之賦形劑，且其中該液體醫藥組成物之pH值介於7.0至7.8範圍內。
  2. 如請求項1所述之液體醫藥組成物，其中該組成物不包含苯酚。
  3. 如請求項1或2所述之液體醫藥組成物，其中索馬魯肽之濃度為0.5至10mg/ml之該組成物。
  4. 如請求項1或2所述之液體醫藥組成物，其中索馬魯肽之濃度為0.1至5mg/ml之該組成物。
  5. 如請求項1或2所述之液體醫藥組成物，其中該緩衝劑為磷酸鹽緩衝劑。
  6. 如請求項1或2所述之液體醫藥組成物，其中該等張劑為丙二醇或氯化鈉。
  7. 如請求項1或2所述之液體醫藥組成物，其中該組成物不包含防腐劑。
  8. 如請求項1或2所述之液體醫藥組成物，其中該非經腸投予為皮下投予。
  9. 如請求項1或2所述之液體醫藥組成物，其中該組成物包含0.5-5mg/ml的索馬魯肽、丙二醇和1.42mg/ml的磷酸氫二鈉二水合物。
  10. 如請求項1或2所述之液體醫藥組成物，其中該組成物包含0.5-5 mg/ml的索馬魯肽、氯化鈉和1.42mg/ml的磷酸氫二鈉二水合物。
  11. 一種套組，其包含用於非經腸投予的液體醫藥組成物及使用說明書，該液體醫藥組成物包含0.1-10mg/ml索馬魯肽及不超過0.01%(w/w)苯酚，其中該液體醫藥組成物為包含至少60% w/w水之水溶液，pH值介於7.0至7.8範圍內，且包含選自由緩衝劑或等張劑組成之群的一或多種醫藥學上可接受之賦形劑。
  12. 一種套組，其包含用於非經腸投予的液體醫藥組成物及注射裝置，該液體醫藥組成物包含0.1-10mg/ml索馬魯肽及不超過0.01%(w/w)苯酚，該注射裝置用於向個體投予該液體醫藥組成物，其中該液體醫藥組成物為包含至少60% w/w水之水溶液，pH值介於7.0至7.8範圍內，且包含選自由緩衝劑或等張劑組成之群的一或多種醫藥學上可接受之賦形劑，且其中該注射裝置選自由耐用筆及預填充筆組成之群。
  13. 如請求項11或12所述之套組，其中該液體醫藥組成物如請求項1至10中任一項所定義。
  14. 一種如請求項1或2所定義之液體醫藥組成物，其用於醫藥。
  15. 一種如請求項1-10中任一項所定義之液體醫藥組成物之用途，其用於製造用於治療糖尿病或肥胖症的醫藥品。
TW107129632A 2017-08-24 2018-08-24 Glp-1組成物及其用途 TWI762706B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17187676 2017-08-24
EP17187676.6 2017-08-24

Publications (2)

Publication Number Publication Date
TW201912147A TW201912147A (zh) 2019-04-01
TWI762706B true TWI762706B (zh) 2022-05-01

Family

ID=59713860

Family Applications (3)

Application Number Title Priority Date Filing Date
TW111139129A TWI847306B (zh) 2017-08-24 2018-08-24 Ｇｌｐ-１組成物及其用途
TW111110149A TWI783890B (zh) 2017-08-24 2018-08-24 Glp-1組成物及其用途
TW107129632A TWI762706B (zh) 2017-08-24 2018-08-24 Glp-1組成物及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TW111139129A TWI847306B (zh) 2017-08-24 2018-08-24 Ｇｌｐ-１組成物及其用途
TW111110149A TWI783890B (zh) 2017-08-24 2018-08-24 Glp-1組成物及其用途

Country Status (24)

Country Link
US (4) US10888605B2 (zh)
EP (2) EP4360651A3 (zh)
JP (1) JP6633777B2 (zh)
KR (1) KR102665710B1 (zh)
CN (1) CN111050750B (zh)
AR (1) AR112480A1 (zh)
AU (2) AU2018321157B2 (zh)
BR (1) BR112020002804A2 (zh)
CA (1) CA3082033A1 (zh)
CL (2) CL2020000422A1 (zh)
CO (1) CO2020002647A2 (zh)
ES (1) ES2976496T3 (zh)
HR (1) HRP20240485T1 (zh)
HU (1) HUE066356T2 (zh)
IL (1) IL272232B1 (zh)
MA (1) MA46990B1 (zh)
MX (1) MX2020001525A (zh)
PE (1) PE20211202A1 (zh)
PH (1) PH12020550051A1 (zh)
PL (1) PL3474820T3 (zh)
RS (1) RS65380B1 (zh)
SG (1) SG11202000940XA (zh)
TW (3) TWI847306B (zh)
WO (1) WO2019038412A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2020127476A1 (en) * 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
WO2020187712A1 (en) * 2019-03-15 2020-09-24 Novo Nordisk A/S Process for spray drying a glp-1 peptide
WO2020190757A1 (en) * 2019-03-15 2020-09-24 Novetide Ltd. Improved processes for the preparation of semaglutide
EP3947451A1 (en) 2019-04-01 2022-02-09 Novo Nordisk A/S Antibodies directed against liraglutide and use thereof
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
WO2021105393A1 (en) * 2019-11-29 2021-06-03 Novo Nordisk A/S Processes for obtaining stable glp-1 compositions
WO2021123228A1 (en) * 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN114146163B (zh) * 2021-12-07 2023-09-26 苏州天马医药集团天吉生物制药有限公司 司美格鲁肽制剂的制备方法
CN114660214B (zh) * 2022-02-18 2024-04-05 兰州积石药业有限公司 一种司美格鲁肽的液相色谱检测方法及其应用
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法
WO2024148155A1 (en) 2023-01-06 2024-07-11 Nano Precision Medical, Inc. Formulations, devices and methods for a glp-1 agonist

Family Cites Families (451)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2444570A (en) 1948-07-06 Drive for counter numeral wheels
GB735443A (en) 1952-09-02 1955-08-24 English Numbering Machines Improvements in or relating to counting devices
US2828742A (en) 1957-05-02 1958-04-01 American Home Prod Cartridge-needle unit
BE639963A (zh) 1963-05-02
US3318289A (en) 1965-05-11 1967-05-09 Northern Ind Products Bi-stable mechanism
CH499734A (de) 1968-07-19 1970-11-30 Kienzle Apparate Gmbh Klinkengesperre als Einrichtungs- und Überholkupplung
US3758683A (en) 1971-04-30 1973-09-11 R Jackson Insulin product
US4282316A (en) 1979-09-11 1981-08-04 Modrovich Ivan Endre Stabilized enzymic solutions for determining urea
GB2072015B (en) 1980-03-21 1983-12-21 Wellcome Found Compositions containing polymyxin
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
GB2109690B (en) 1981-02-12 1985-02-20 Robert Charles Turner Dose metering plunger devices for use with syringes
US4568335A (en) 1981-08-28 1986-02-04 Markwell Medical Institute, Inc. Device for the controlled infusion of medications
DE3204178C2 (de) 1982-02-06 1986-03-20 Eppendorf Gerätebau Netheler + Hinz GmbH, 2000 Hamburg Pipettiervorrichtung
US4483849A (en) 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
GB2141799B (en) 1983-06-03 1986-07-16 Diehl Gmbh & Co An adjusting ratchet mechanism for a time switch
DE3468173D1 (en) 1983-09-07 1988-02-04 Disetronic Ag Portable infusion apparatus
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60129941U (ja) 1984-02-09 1985-08-31 テルモ株式会社 医療用器具
US4592745A (en) 1984-02-29 1986-06-03 Novo Industri A/S Dispenser
FR2583291A1 (fr) 1985-06-14 1986-12-19 Hazon Bernard Dispositif d'avancement pas a pas du piston de seringues par double vis coaxiale avec controle du debit d'injection. application aux injections medicamenteuses intra-dermiques repetitives
DE3546150A1 (de) 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
DE3670768D1 (de) 1985-11-08 1990-06-07 Disetronic Ag Injektionsgeraet.
DE3609555A1 (de) 1986-03-21 1987-09-24 Josef Porner Blutentnahmespritze
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
EP1498425A1 (en) 1986-05-05 2005-01-19 The General Hospital Corporation Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
DE3645245C2 (de) 1986-11-14 1994-01-27 Haselmeier Wilhelm Fa Injektionsgerät
US5716990A (en) 1987-03-09 1998-02-10 Cancer Research Campaign Technology Limited Drug delivery systems
DK177187A (da) 1987-04-07 1988-10-08 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glasampul
DE3715258C2 (de) 1987-05-08 1996-10-31 Haselmeier Wilhelm Fa Injektionsgerät
AU616411B2 (en) 1987-05-14 1991-10-31 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
GB8713810D0 (en) 1987-06-12 1987-07-15 Hypoguard Uk Ltd Measured dose dispensing device
FI883338A (fi) 1987-07-16 1989-01-17 Bristol Myers Co Vattenloesningar av doxorubicinhydroklorid.
IT1222331B (it) 1987-08-25 1990-09-05 Bruno Micovilovich Siringa di sicurezza per usi parentali,a disimpegno autonomo e rapido dell'ago dopo l'uso
US4919596A (en) 1987-12-04 1990-04-24 Pacesetter Infusion, Ltd. Fluid delivery control and monitoring apparatus for a medication infusion system
US4833379A (en) 1988-01-13 1989-05-23 Sherwood Medical Company Motor control fail-safe circuit
CH675078A5 (zh) 1988-01-22 1990-08-31 Nosta Ag
DE3900926C2 (de) 1988-02-08 1999-05-12 Disetronic Licensing Ag Spritzenförmiges Injektionsgerät und Injektionsgerätebaukasten
DK166948B1 (da) 1988-02-10 1993-08-09 Dcp Af 1988 As Doseringsenhed til dosering af et antal afmaalte maengder af en vaeske, saasom insulin, fra en glastubule
US4973318A (en) 1988-02-10 1990-11-27 D.C.P. Af 1988 A/S Disposable syringe
WO1990000200A1 (en) 1988-06-27 1990-01-11 Genex Corporation Thermal release of recombinant protein into culture media
DE58908873D1 (de) 1988-09-12 1995-02-23 Graesslin Kg Richtgesperre für eine Schaltuhr.
GB8900763D0 (en) 1989-01-13 1989-03-08 Kabi Vitrum Peptide Hormones A Multi-dose syringe
US5216437A (en) 1989-02-02 1993-06-01 Canon Kabushiki Kaisha Ink, and recording method making use of same
DK68789A (da) 1989-02-14 1990-08-15 Novo Nordisk As Injektionspen
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
DE68929217T2 (de) 1989-03-20 2000-11-30 The General Hospital Corp., Boston Insulinotropes hormon
JP2822447B2 (ja) 1989-05-19 1998-11-11 住友電気工業株式会社 酸化物超電導線材の製造方法および装置
US4994033A (en) 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5226895A (en) 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
DE3927286C2 (de) 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
US5216011A (en) 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE69013471T2 (de) 1989-12-05 1995-03-30 Merck & Co Inc Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DK17890A (da) 1990-01-22 1991-07-23 Novo Nordisk As Fremgangsmaade og apparat til opblanding og injicering af et laegemiddel
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
GB9007113D0 (en) 1990-03-29 1990-05-30 Sams Bernard Dispensing device
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5226896A (en) 1990-04-04 1993-07-13 Eli Lilly And Company Dose indicating injection pen
IT220491Z2 (it) 1990-04-13 1993-09-24 Stilolinea Srl Penna a sfera del tipo a punta scrivente rientrante
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5257987A (en) 1990-05-21 1993-11-02 Pharmetrix Corporation Controlled release osmotic infusion system
JP3042710B2 (ja) 1990-09-21 2000-05-22 ノボ ノルディスク アクティーゼルスカブ ペンシリンジアセンブリー
US5284480A (en) 1990-11-09 1994-02-08 Medtronic, Inc. Inflation/deflation syringe with threaded plunger
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
US5331954A (en) 1990-12-21 1994-07-26 Novo Nordisk A/S Device for nasal delivery of liquid medications
US5232706A (en) 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
AU641206B2 (en) 1991-01-22 1993-09-16 Eli Lilly And Company Multiple dose injection pen
EP0498737B1 (en) 1991-02-07 1995-07-19 Terumo Kabushiki Kaisha Dosing means for an injector
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5571719A (en) 1991-03-27 1996-11-05 Novo Nordisk A/S Catalase, its production and use
US5258377A (en) 1991-04-08 1993-11-02 Taiho Pharmaceutical Co., Ltd. 2-spirocyclopropyl 4-acylcephems
DE4112259A1 (de) 1991-04-15 1992-10-22 Medico Dev Investment Co Injektionsgeraet
DK68991D0 (da) 1991-04-17 1991-04-17 Novo Nordisk As Manifold
US5645052A (en) 1991-04-26 1997-07-08 The Boc Group Plc Anaesthetic vaporizer with expandable/contractable reservoir for pumping liquid anaesthetic
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
EP0525525B1 (de) 1991-07-24 1995-05-03 Medico Development Investment Company Injektor
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5611783A (en) 1991-11-29 1997-03-18 Novo Nordisk A/S Pen-shaped syringe
DK194291D0 (da) 1991-11-29 1991-11-29 Novo Nordisk As Sproejte til automatisk injektion.
US5246417A (en) 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
FR2686460B1 (fr) 1992-01-20 1994-03-11 Labinal Precision Mecanique Organe de contact electrique femelle.
US5279585A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Medication delivery pen having improved dose delivery features
CH682968B5 (fr) 1992-02-12 1994-06-30 Rolex Montres Procédé de fabrication d'un joint et joint pour dispositif de commande étanche pour montre obtenu selon ce procédé.
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
DE4208677A1 (de) 1992-03-18 1993-09-23 Injecta Gmbh Steinach Injektionsvorrichtung, insbesondere fuer sehgeschaedigte diabetiker
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
EP0632734B1 (en) 1992-03-25 1998-06-10 Tebro S.A. Powder jet dispenser for medicament inhalation therapies
US5271527A (en) 1992-04-02 1993-12-21 Habley Medical Technology Corporation Reusable pharmaceutical dispenser with full stroke indicator
US5281198A (en) 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
UA26190C2 (uk) 1992-07-28 1999-07-19 Сейфтек Ай Лімітед Шприц
GB9219849D0 (en) 1992-09-19 1992-10-28 Hypoguard Uk Ltd Device
ES2154651T3 (es) 1992-10-15 2001-04-16 Gen Hospital Corp Bomba de infusion con biblioteca de medicamentos cargable electronicamente.
US5545147A (en) 1992-10-20 1996-08-13 Eli Lilly And Company Anti-backup improvement for hypodermic syringes
US5378233A (en) 1992-11-18 1995-01-03 Habley Medical Technology Corporation Selected dose pharmaceutical dispenser
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
GB9226423D0 (en) 1992-12-18 1993-02-10 Sams Bernard Incrementing mechanisms
CZ284900B6 (cs) 1993-02-19 1999-04-14 Medicorp Holding S.A. Předem naplněná stříkačka pro uložení a vydávání kapalné a sterilní léčebné látky
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
US5584815A (en) 1993-04-02 1996-12-17 Eli Lilly And Company Multi-cartridge medication injection device
ZA941881B (en) 1993-04-02 1995-09-18 Lilly Co Eli Manifold medication injection apparatus and method
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
SE9301494D0 (sv) 1993-04-30 1993-04-30 Kabi Pharmacia Ab A device for dosing liquid preparation
DK52393D0 (zh) 1993-05-05 1993-05-05 Novo Nordisk As
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
PL178466B1 (pl) 1993-09-17 2000-05-31 Novo Nordisk As Pochodna insuliny i kompozycja farmaceutyczna do leczenia cukrzycy
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
JPH09505290A (ja) 1993-11-19 1997-05-27 ジー．ディー．サール アンド カンパニー Ｎ‐［Ｎ‐［５‐［４‐（アミノイミノメチル）フェニル］‐１‐オキソペンチル］‐Ｌ‐α‐アスパルチル］‐Ｌ‐フェニルアラニンまたはそのエステル並びにそれらの医薬的に許容される塩類の経皮的組成物
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5478316A (en) 1994-02-02 1995-12-26 Becton, Dickinson And Company Automatic self-injection device
US5514097A (en) 1994-02-14 1996-05-07 Genentech, Inc. Self administered injection pen apparatus and method
US5562623A (en) 1994-02-14 1996-10-08 Univec Single-use syringe assembly including spring clip lock and plunger
AU1847695A (en) 1994-02-22 1995-09-04 Syntex-Synergen Neuroscience Joint Venture, The Pharmaceutical formulations of cntf
WO1995029996A1 (en) 1994-05-03 1995-11-09 Novo Nordisk A/S Alkaline glucose oxidase
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5750140A (en) 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU1595395A (en) 1994-06-15 1996-01-05 Interventional Research Technologies, Inc. Locking device for syringe or like instrument
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5827232A (en) 1994-06-22 1998-10-27 Becton Dickinson And Company Quick connect medication delivery pen
US5725508A (en) 1994-06-22 1998-03-10 Becton Dickinson And Company Quick connect medication delivery pen
US5440976A (en) 1994-08-23 1995-08-15 Fred Giuliano Adjustable dispensing stirrer for soluble sweeteners
CA2186869A1 (en) 1994-08-24 1996-02-29 Hideto Yamagata Injection apparatus
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5549574A (en) 1994-08-30 1996-08-27 Eli Lilly And Company Cartridge assembly for use in a pen-type medicament injector
DE69532492T2 (de) 1994-08-31 2004-12-02 Mitsubishi Pharma Corp. Verfahren zur Reinigung von rekombinantem menschlichem Serumalbumin
CN1157553A (zh) 1994-09-09 1997-08-20 诺沃挪第克公司 清洁、消毒和防护隐形眼镜的方法
US5549575A (en) 1994-09-13 1996-08-27 Becton Dickinson And Company Cartridge retainer assembly for medication delivery pen
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
BR9508847A (pt) 1994-09-20 1999-11-30 Novo Nordisk A S E Slagterisel Processo para tratar uma solução aquosa de proteìna e para produzir um gênero alimentìcio à base de carne, mistura de solução de proteìna/hidrolisado tratada com calor, ou hidrolisado lìquido tratado com calor, gênero alimentìcio à base de carne e uso da mistura de solução de proteìna/hidrolisado tratada com calor, ou de hidrolisado lìquido tratado com calor
ZA958073B (en) 1994-09-28 1996-04-23 Anthony William Manicom Method of and apparatus for administering a drug to a patient
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (ja) 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１組成物
DE69637940D1 (de) 1995-02-03 2009-07-09 Novozymes As Eine methode zum entwurf von alpha-amylase mutanten mit vorbestimmten eigenschaften
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2213682C (en) 1995-03-07 2009-10-06 Eli Lilly And Company Recyclable medication dispensing device
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
EP0871665B1 (en) 1995-03-17 2003-07-23 Novo Nordisk A/S Insulin derivatives
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK0828753T3 (da) 1995-06-02 2003-06-30 Novozymes As A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering
DK0840628T3 (da) 1995-06-02 2002-10-07 Novo Nordisk As Automatisk tilbagetrækning af stempelstang
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
DE69621131T2 (de) 1995-06-13 2002-11-28 Novozymes A/S, Bagsvaerd 4-substituierte-phenylboronsäuren als enzymstabilisatoren
US5688251A (en) 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
US5899879A (en) 1995-12-19 1999-05-04 Genesis Medical Technologies, Inc. Spring-actuated needleless injector
PL185539B1 (pl) 1996-02-23 2003-05-30 Novo Nordisk As Strzykawka z mechanizmem ustalania dawek i elektronicznym przedstawianiem parametrów
PT885014E (pt) 1996-03-05 2003-02-28 Robert Gurny Composicoes farmaceuticas contendo polimeros orto ester tamponados
US6277098B1 (en) 1996-03-12 2001-08-21 Novo Nordisk A/S Injection device with electronic presentation of set doses
DE59609513D1 (de) 1996-04-02 2002-09-05 Disetronic Licensing Ag Injektionsgerät
CA2252620A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S Injection needle
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
AU737664B2 (en) 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998001170A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Automatic needle insertion mechanism
HUP9904152A3 (en) 1996-07-05 2000-05-29 Novo Nordisk As Flexible piston rod
CA2258308A1 (en) 1996-07-05 1998-01-15 Novo Nordisk A/S Dose setting device
US5981489A (en) 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
US5962407A (en) 1996-07-26 1999-10-05 Kelly; Michael T. Loloatin derivatives and analogs
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
PT966297E (pt) 1996-08-08 2009-03-18 Amylin Pharmaceuticals Inc Regulação da motilidade gastrintestinal
US5843036A (en) 1996-08-23 1998-12-01 Becton Dickinson And Company Non-dosing cartridge for an injection device
US5709662A (en) 1996-08-23 1998-01-20 Becton Dickinson France, S.A. Cartridge for an injection device
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6379339B1 (en) 1996-09-13 2002-04-30 Nova Nordisk A/S Syringe
US6110149A (en) 1996-09-13 2000-08-29 Novo Nordisk A/S Syringe
US5947934A (en) 1996-09-13 1999-09-07 Novo Nordisk A/S Dose display for an injection syringe
JP3989966B2 (ja) 1996-09-13 2007-10-10 ノボ ノルディスク アクティーゼルスカブ 注入式注射器用投薬量ディスプレイ
EP0927055B1 (en) 1996-09-20 2001-12-05 Novo Nordisk A/S Working cylinder
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW524667B (en) 1996-12-05 2003-03-21 Pfizer Parasiticidal pyrazoles
US5954689A (en) 1996-12-20 1999-09-21 Novo Nordisk A/S Jet injector
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR20000070338A (ko) 1997-01-20 2000-11-25 나가시마 카쭈시게, 노미야마 아키히코 펩티드의 안정화 방법 및 당해 방법을 이용한 펩티드 함유 동결건조 의약조성물
GB2321419B (en) 1997-01-27 2001-02-07 Medic Aid Ltd Atomizer
WO1998033538A1 (en) 1997-02-04 1998-08-06 Novo Nordisk A/S A device for the administration of a liquid medicament suspension
DE29703820U1 (de) 1997-03-03 1998-07-02 Medico Development Investment Co., Ascona Injektionsgerät
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6277097B1 (en) 1997-03-25 2001-08-21 Novo Nordisk A/S Injection system
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
RU2111019C1 (ru) 1997-05-22 1998-05-20 Сергей Александрович Хворостов Универсальный инъектор
SK159599A3 (en) 1997-05-23 2000-11-07 Predrag Sikiric New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6074372A (en) 1997-06-09 2000-06-13 Novo Nordisk A/S Dose setting mechanism and an injection syringe having such a dose setting mechanism
US6003736A (en) 1997-06-09 1999-12-21 Novo Nordisk A/S Device for controlled dispensing of a dose of a liquid contained in a cartridge
US6207684B1 (en) 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
US5961496A (en) 1997-06-17 1999-10-05 Novo Nordisk A/S Syringe with tiltable nut for quick piston disengagement
US6796970B1 (en) 1997-06-17 2004-09-28 Novo Nordisk A/S Dose setting device
JP3503129B2 (ja) 1997-06-30 2004-03-02 荒川化学工業株式会社 カラーフィルタ層用剥離剤およびカラーフィルタ用ガラス基板の再生方法
WO1999002210A1 (en) 1997-07-11 1999-01-21 Novo Nordisk A/S An apparatus for the registration of the setting of a medical device
JP2003514586A (ja) 1997-07-14 2003-04-22 ノボ ノルディスク アクティーゼルスカブ 円筒状アンプル
WO1999003521A1 (en) 1997-07-14 1999-01-28 Novo Nordisk A/S Injection member
DE19730999C1 (de) 1997-07-18 1998-12-10 Disetronic Licensing Ag Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US5957896A (en) 1997-08-11 1999-09-28 Becton, Dickinson And Company Medication delivery pen
FR2767479B1 (fr) 1997-08-22 1999-10-22 Aguettant Lab Dispositif d'injection de medicament
AU9202398A (en) 1997-09-29 1999-04-23 Becton Dickinson & Company Injection device and drug cartridge for preventing cross-use of the device and drug cartridge
EP2042161A1 (en) 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
DE69813599T2 (de) 1997-10-24 2004-04-08 Genentech, Inc., South San Francisco Reinigung von molekülen
IL135400A0 (en) 1997-10-24 2001-05-20 Novo Nordisk As Aggregates of human insulin derivatives
US6312413B1 (en) 1997-10-30 2001-11-06 Novo Nordisk A/S Cylinder ampoule
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
DE29721752U1 (de) 1997-12-09 1998-02-12 Siemens AG, 80333 München Crimpkontakt für Stecksysteme
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JPH11249087A (ja) 1997-12-18 1999-09-17 Tome:Kk コンタクトレンズ用液剤
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
JP4353544B2 (ja) 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
CA2284847A1 (en) 1998-01-30 1999-08-05 Suntory Limited Process for producing peptides using a helper peptide
ES2153711T3 (es) 1998-01-30 2001-03-01 Novo Nordisk As Jeringuilla de inyeccion.
US6770288B2 (en) 1998-02-13 2004-08-03 Pfizer Products Inc. Drug delivery system
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
ES2356595T3 (es) 1998-02-13 2011-04-11 Amylin Pharmaceuticals, Inc. Nuevos compuestos de actividad mixta de la amilina.
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
US6221053B1 (en) 1998-02-20 2001-04-24 Becton, Dickinson And Company Multi-featured medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
AU2612599A (en) 1998-03-13 1999-10-11 Novo Nordisk A/S Stabilized aqueous peptide solutions
AU3772199A (en) 1998-05-01 1999-11-23 University Of Tennessee Research Corporation, The Flow cytometric characterization of amyloid fibrils
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
AU4769599A (en) 1998-07-08 2000-02-01 Novo Nordisk A/S A medical delivery device and a cartridge assembly for use in the same
CN1317967A (zh) 1998-09-17 2001-10-17 伊莱利利公司 蛋白质制剂
US6033376A (en) 1998-09-30 2000-03-07 Allergan Sales, Inc. Wound shaper sleeve
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US6605067B1 (en) 1998-11-20 2003-08-12 Novo Nordisk A/S Injection needle
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
WO2000037098A1 (en) 1998-12-22 2000-06-29 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
DE29900482U1 (de) 1999-01-14 2000-08-31 Medico Development Investment Co., Ascona Injektionsgerät
DE60021166T3 (de) 1999-01-14 2019-08-22 Amylin Pharmaceuticals, Llc Neue exendin agonist formulierungen und deren verabreichung
AU3421600A (en) 1999-02-14 2000-08-29 Ing. Erich Pfeiffer Gmbh Dispenser for flowable media
US6258062B1 (en) 1999-02-25 2001-07-10 Joseph M. Thielen Enclosed container power supply for a needleless injector
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
IL144989A0 (en) 1999-03-17 2002-06-30 Novo Nordisk As Method for acylating peptides and novel acylating agents
SE9901366D0 (sv) 1999-04-16 1999-04-16 Pharmacia & Upjohn Ab Injector device and method for its operation
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
KR20020059255A (ko) 1999-06-17 2002-07-12 린다 에스. 스티븐슨 저온 저장을 개선하기 위한 ＰＥＧ-Ｈｂ를 사용하는 연속심장 관류 보존
AU5325200A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
ES2258469T3 (es) 1999-08-05 2006-09-01 Becton Dickinson And Company Lapiz de administracion de medicacion.
TW453884B (en) 1999-09-16 2001-09-11 Novo Nordisk As Dose setting limiter
CA2383574A1 (en) 1999-09-20 2001-03-29 Eli Lilly And Company Method for reducing the risk of cancer
US6514230B1 (en) 1999-10-12 2003-02-04 Novo Nordisk A/S Air shot mechanism for electronic injection devices
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
PL355378A1 (en) 1999-12-16 2004-04-19 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1250126A2 (en) 2000-01-11 2002-10-23 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US7598222B2 (en) 2000-01-27 2009-10-06 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
GB0007071D0 (en) 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
US6692472B2 (en) 2000-05-04 2004-02-17 Novo Nordisk A/S Injection device, a preassembled dose setting and injection mechanism for an injection device, and a method of assembling an injection device
CA2380423A1 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US6716198B2 (en) 2000-05-18 2004-04-06 Novo Nordisk A/S Injection device
US6547763B2 (en) 2000-05-18 2003-04-15 Novo Nordisk A/S Dose display for injection device
US6547764B2 (en) 2000-05-31 2003-04-15 Novo Nordisk A/S Double pointed injection needle
DK1695983T3 (da) 2000-06-16 2009-05-18 Lilly Co Eli Glucagon-lignende peptid-1 analoger
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
US6369419B1 (en) 2000-06-23 2002-04-09 International Business Machines Corporation Self-aligned near surface strap for high density trench DRAMS
ATE386563T1 (de) 2000-07-14 2008-03-15 Novo Nordisk As Flüssigkeitsabgabevorrichtung und verfahren zum vermindern des tröpfelns
WO2002024257A1 (en) 2000-09-22 2002-03-28 Novo Nordisk A/S A medication delivery device
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
KR20080085082A (ko) 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EP1361908B1 (en) 2001-02-14 2007-12-19 Novo Nordisk A/S Electronically controlled injection or infusion device
CA2436399A1 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
AU2002235731A1 (en) 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
EP1776975B1 (en) 2001-05-16 2011-06-22 Eli Lilly & Company Medication injector apparatus with drive assembly that facilitates reset
US20040156835A1 (en) 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
GB0113881D0 (en) 2001-06-07 2001-08-01 Innovate Biomed Ltd Foil cutting system
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp－1和基础胰岛素的预混合物
US6676641B2 (en) 2001-09-05 2004-01-13 Futura Medical Technologies, Inc. Retractable hypodermic syringe
HUP0700151A2 (en) 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CA2463803A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
BR0307727A (pt) 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
CN1652813A (zh) 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
WO2003084563A1 (en) 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
MXPA05000413A (es) 2002-07-09 2005-07-22 Sandoz Ag Formulaciones liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden 1,2-propilenglicol.
EP1521607A1 (en) 2002-07-10 2005-04-13 Novo Nordisk A/S An injection device with a dose setting limiter
US6945961B2 (en) 2002-07-10 2005-09-20 Novo Nordisk A/S Injection device
EP1391794A1 (en) 2002-07-23 2004-02-25 Novo Nordisk A/S Device with time indicating means
ATE331542T1 (de) 2002-08-29 2006-07-15 Novo Nordisk As Injektionsvorrichtung mit frontladung
CA2500195C (en) 2002-09-24 2009-07-21 Shl Medical Ab Injecting device
ES2308029T3 (es) 2002-09-25 2008-12-01 Novo Nordisk A/S Proceso de purificacion que comprende una microfiltracion a temperaturas elevadas.
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
AU2003278929A1 (en) 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
AU2003297356A1 (en) 2002-12-17 2004-07-14 Amylin Pharmaceuticals, Inc. Prevention and treatment of cardiac arrhythmias
WO2004066939A2 (en) 2003-01-27 2004-08-12 Sarnoff Corporation Controlled-release drug delivery system
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0304824D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
GB0306642D0 (en) 2003-03-22 2003-04-30 Dca Design Int Ltd Improvements in and relating to an injector for a medical product
GB0308267D0 (en) 2003-04-10 2003-05-14 Dca Design Int Ltd Improvements in and relating to a pen-type injector
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2004105781A2 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
CN1812807A (zh) * 2003-06-03 2006-08-02 诺沃挪第克公司 稳定化的药物肽组合物
SI1656170T1 (sl) 2003-08-12 2019-05-31 Eli Lilly And Company Oprema za izdajanje zdravil s trojnim vijačnim navojem za mehanski pospešek
WO2005021026A2 (en) 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Methods for treating or ameliorating ghrelin-associated diseases and disorders
BR122019021416A2 (zh) 2003-09-19 2019-12-21
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP1684793B1 (en) 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
CN113304250A (zh) * 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1694278A4 (en) 2003-12-16 2009-08-12 Ipsen Pharma GLP-1 PHARMACEUTICAL COMPOSITIONS
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
US7448385B2 (en) 2004-06-07 2008-11-11 Purepharm Inc. Nasal adaptation of an oral inhaler device
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
US20080125361A1 (en) 2004-11-12 2008-05-29 Novo Nordisk A/S Stable Formulations Of Peptides
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
DK1843809T3 (en) 2005-01-21 2017-07-31 Novo Nordisk As AUTOMATIC INJECTION DEVICE WITH A TOP TRANSMISSION MECHANISM
NZ561137A (en) 2005-03-08 2011-09-30 Pharmacia & Upjohn Co Llc Stable anti-CTLA-4 antibody compositions with chelating agents
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007014051A2 (en) 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
US8389472B2 (en) 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
JP2009519962A (ja) 2005-12-19 2009-05-21 コメンティス，インコーポレーテッド 眼投与用局所メカミルアミン製剤およびその使用
ES2572736T3 (es) 2005-12-29 2016-06-02 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunógena para atenuar síntomas clínicos en cerdos
MX2008013168A (es) 2006-04-13 2008-10-27 Sod Conseils Rech Applic Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
KR20090039787A (ko) 2006-07-18 2009-04-22 센토코 인코포레이티드 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
UY30820A1 (es) 2006-12-21 2008-07-03 Centocor Inc Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
KR20100056515A (ko) 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
WO2009051992A1 (en) 2007-10-19 2009-04-23 Bausch & Lomb Incorporated Compositions and methods for treating diseases involving ocular angiogenesis by inhibiting one or more selected receptor tyrosine kinases
US20100323955A1 (en) 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2009075859A2 (en) 2007-12-11 2009-06-18 Conjuchem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
JP5703226B2 (ja) 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
US20120136298A1 (en) 2009-06-04 2012-05-31 Novo Nordisk Healthcare A/G Mixing device with piston coupling arrangement
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
JP5738291B2 (ja) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリンリンカー複合体を含むプロドラッグ
WO2011050008A2 (en) 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
CN102652015B (zh) 2009-12-10 2016-08-03 默克专利有限公司 包含寡肽、优选西仑吉肽的药物组合物
CN104311657B (zh) 2009-12-16 2020-12-08 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR20130101005A (ko) 2010-07-28 2013-09-12 아밀린 파마슈티칼스, 엘엘씨. 안정화된 영역을 갖는 glp-1 수용체 효능제 화합물
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2012062803A1 (en) 2010-11-09 2012-05-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20140045754A1 (en) 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
CA2826506C (en) 2011-02-04 2017-07-25 Biocopea Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US9132170B2 (en) 2011-07-29 2015-09-15 Case Western Reserve University Compositions and methods for treating cognitive deficits
US9758560B2 (en) 2011-09-06 2017-09-12 Novo Nordisk A/S GLP-1 derivatives
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN104244981A (zh) 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
CN104185639B (zh) 2012-03-01 2018-06-19 诺和诺德股份有限公司 Glp-1前体药物
CN102579350B (zh) 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CA2868688A1 (en) 2012-04-03 2013-10-10 Trustees Of Boston University Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
WO2013156594A1 (en) 2012-04-19 2013-10-24 Novo Nordisk A/S Human amylin analogues
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
CN104519902B (zh) 2012-05-08 2017-10-27 诺和诺德股份有限公司 双酰化glp‑1衍生物
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
KR101720885B1 (ko) 2012-06-19 2017-03-28 데비오팜 인터네셔날 에스 에이 (e)-n-메틸-n-((3-메틸벤조푸란-2-일)메틸)-3-(7-옥소-5,6,7,8-테트라히드로-1,8-나프티리딘-3-일)아크릴아미드의전구약물 유도체
EP3689365A1 (en) 2012-07-01 2020-08-05 Novo Nordisk A/S Use of long-acting glp-1 peptides
US20150273069A1 (en) * 2012-10-17 2015-10-01 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
AU2014228460B2 (en) 2013-03-15 2018-11-01 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014202780A1 (en) 2013-06-21 2014-12-24 Novo Nordisk A/S Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
CA2952969A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Llc Pharmaceutical compositions
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
WO2016038521A1 (en) 2014-09-08 2016-03-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of liraglutide
ES2739289T3 (es) * 2014-11-27 2020-01-30 Novo Nordisk As Derivados de GLP-1 y sus usos
CN105777872B (zh) * 2014-12-16 2019-06-07 深圳翰宇药业股份有限公司 一种萨摩鲁肽的纯化方法
CN107249620B (zh) 2015-05-13 2018-06-26 杭州九源基因工程有限公司 一种包含glp-1类似物的药物制剂及其制备方法
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017149070A1 (en) 2016-03-03 2017-09-08 Novo Nordisk A/S Glp-1 derivatives and uses thereof
AU2017256774B2 (en) 2016-04-28 2024-07-11 Novo Nordisk A/S Semaglutide in cardiovascular conditions
US20190374613A1 (en) 2016-11-22 2019-12-12 Biocon Research Limited Pharmaceutical compositions of glp-1 analogues
GB201621987D0 (en) 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
KR20190124704A (ko) 2017-01-24 2019-11-05 마크레젠, 인크. 아포지질단백질 모방체를 이용하는, 나이 관련 황반 변성 및 기타 안질환의 치료
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
AR114162A1 (es) 2017-12-21 2020-07-29 Sanofi Sa Composición farmacéutica líquida
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Also Published As

Publication number Publication date
PL3474820T3 (pl) 2024-05-13
CN111050750A (zh) 2020-04-21
AU2018321157B2 (en) 2024-03-28
AU2024204151A1 (en) 2024-07-11
US10888605B2 (en) 2021-01-12
CL2021001430A1 (es) 2021-11-12
PE20211202A1 (es) 2021-07-05
CN111050750B (zh) 2024-09-24
HUE066356T2 (hu) 2024-07-28
HRP20240485T1 (hr) 2024-07-05
IL272232A (en) 2020-03-31
US20200164042A1 (en) 2020-05-28
PH12020550051A1 (en) 2020-10-19
SG11202000940XA (en) 2020-02-27
TW202224670A (zh) 2022-07-01
IL272232B1 (en) 2023-03-01
TW201912147A (zh) 2019-04-01
US20210085755A1 (en) 2021-03-25
TW202304501A (zh) 2023-02-01
MA46990B1 (fr) 2024-03-29
AR112480A1 (es) 2019-10-30
JP2019528237A (ja) 2019-10-10
MA46990A (fr) 2019-05-01
ES2976496T3 (es) 2024-08-02
TWI783890B (zh) 2022-11-11
EP3474820B1 (en) 2024-02-07
US11752198B2 (en) 2023-09-12
CL2020000422A1 (es) 2020-07-10
MX2020001525A (es) 2020-03-20
WO2019038412A1 (en) 2019-02-28
CA3082033A1 (en) 2019-02-28
CO2020002647A2 (es) 2020-06-09
EP4360651A2 (en) 2024-05-01
EP3474820C0 (en) 2024-02-07
EP4360651A3 (en) 2024-07-17
US20240216475A1 (en) 2024-07-04
US20240016896A1 (en) 2024-01-18
JP6633777B2 (ja) 2020-01-22
BR112020002804A2 (pt) 2020-07-28
RS65380B1 (sr) 2024-04-30
RU2020109402A (ru) 2021-09-03
KR102665710B1 (ko) 2024-05-14
RU2020109402A3 (zh) 2022-01-25
TWI847306B (zh) 2024-07-01
AU2018321157A1 (en) 2020-03-19
KR20200044016A (ko) 2020-04-28
EP3474820A1 (en) 2019-05-01

Similar Documents

Publication Publication Date Title
TWI762706B (zh) Glp-1組成物及其用途
AU2019363725B2 (en) Stable semaglutide compositions and uses thereof
RU2777600C2 (ru) Композиции на основе glp-1 и пути их применения
RU2803237C2 (ru) Стабильные композиции на основе семаглутида и их варианты применения
AU2024204972A1 (en) Stable semaglutide compositions and uses thereof
KR20230158563A (ko) 시클로덱스트린을 포함하는 약학적 제형
WO2023110833A1 (en) Pharmaceutical formulations comprising a cyclodextrin